AR109498A1 - TREATMENT OF SCALE CARCINOMAS WITH ERK INHIBITORS - Google Patents

TREATMENT OF SCALE CARCINOMAS WITH ERK INHIBITORS

Info

Publication number
AR109498A1
AR109498A1 ARP170101684A ARP170101684A AR109498A1 AR 109498 A1 AR109498 A1 AR 109498A1 AR P170101684 A ARP170101684 A AR P170101684A AR P170101684 A ARP170101684 A AR P170101684A AR 109498 A1 AR109498 A1 AR 109498A1
Authority
AR
Argentina
Prior art keywords
carcinomas
scale
treatment
erk inhibitors
subject
Prior art date
Application number
ARP170101684A
Other languages
Spanish (es)
Inventor
Linda Kessler
Dana Hu-Lowe
Francis Burrows
Original Assignee
Kura Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kura Oncology Inc filed Critical Kura Oncology Inc
Publication of AR109498A1 publication Critical patent/AR109498A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un método de tratar cáncer en un sujeto que así lo necesite, caracterizado porque comprende administrar una dosis eficaz de un inhibidor de una quinasa regulada por señales extracelulares (ERK) al sujeto, en donde dicho sujeto comprende un genoma que exhibe amplificación y/o sobreexpresión de por lo menos un gen que se localiza en el cromosoma 11q13.3-13.4.Claim 1: A method of treating cancer in a subject in need thereof, characterized in that it comprises administering an effective dose of an extracellular signal-regulated kinase inhibitor (ERK) to the subject, wherein said subject comprises a genome that exhibits amplification and / or overexpression of at least one gene that is located on chromosome 11q13.3-13.4.

ARP170101684A 2016-06-20 2017-06-19 TREATMENT OF SCALE CARCINOMAS WITH ERK INHIBITORS AR109498A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662352533P 2016-06-20 2016-06-20

Publications (1)

Publication Number Publication Date
AR109498A1 true AR109498A1 (en) 2018-12-19

Family

ID=64755048

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101684A AR109498A1 (en) 2016-06-20 2017-06-19 TREATMENT OF SCALE CARCINOMAS WITH ERK INHIBITORS

Country Status (1)

Country Link
AR (1) AR109498A1 (en)

Similar Documents

Publication Publication Date Title
CO2019007839A2 (en) Compositions and methods for inhibiting the action of arginase
CL2018003213A1 (en) Enzymatic inhibitors
CL2020002082A1 (en) PD-1 / PD-L1 inhibitors.
MX2017008844A (en) Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease.
CL2018000853A1 (en) Combination therapy of bromodomain inhibitors and blocking immune control points to treat cancer.
BR112019003914A2 (en) inhibitors of cellular metabolic processes
ZA201906269B (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
PH12020550936A1 (en) Combination drug including tlr7 agonist
MX2018008346A (en) Oncolytic virus and checkpoint inhibitor combination therapy.
MX2016013027A (en) Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer.
MX2022008868A (en) Treatment of cancer with tg02.
MX2018006674A (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor.
AR080643A1 (en) IDENTIFICATION OF THE LKB1 MUTATION AS A PREDICTIVE BIOMARCATOR FOR SENSITIVITY TO INHIBITORS OF THE TOR QUINASA
MY185579A (en) Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
NI201400110A (en) CANCER TREATMENT WITH TOR KINASE INHIBITORS
EA201692285A1 (en) EZH2 INHIBITORS FOR TREATING LYMPHOMA
NI201400109A (en) CANCER TREATMENT WITH TOR KINASE INHIBITORS
AR116121A1 (en) CANCER TREATMENT METHODS
CO2017004784A2 (en) Acid-1 - [(3-chloro-2-fluoro-phenyl) methyl] -4 - [[3-fluoro-6 - [(5-methyl-1h-pyrazol-3-yl) amino] -2- isomers pyridyl] methyl] -2-methyl-piperidine-4-carboxylic acid as inhibitors of aurora kinase a
MX2020013163A (en) Methods of treating malignant lymphoproliferative disorders.
MX2017009246A (en) Combination drug.
BR112017027277A2 (en) ? method for treating or preventing a disease and methods for killing a cell?
CO2021007006A2 (en) Modulators of irf5 expression
MX2019006694A (en) Oxabicycloheptanes for modulation of immune response.
MX2020012782A (en) Ccr5 inhibitor for use in treating cancer.

Legal Events

Date Code Title Description
FB Suspension of granting procedure